A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Condition:   Cytomegalovirus Infection Interventions:   Biological: mRNA-1647;   Biological: Placebo Sponsor:   ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials